22:50 , Sep 28, 2018 |  BC Extra  |  Company News

Management tracks: Zai, Selecta

Zai Lab Ltd. (NASDAQ:ZLAB) hired Tao Fu as COO. Fu was EVP and chief commercial and business officer of Portola Pharmaceuticals Inc. (NASDAQ:PTLA) (see "Amid Launch Troubles, Portola Commercial Chief Fu Resigns"). Prior to Portola, he...
04:48 , May 17, 2018 |  BC Extra  |  Financial News

Abpro withdraws IPO

Antibody company Abpro Corp. (Woburn, Mass.) is withdrawing a planned IPO on NASDAQ, according to an SEC filing on May 16. Underwriters were to be UBS, Wells Fargo, Nomura and Oppenheimer. Earlier this month, Abpro said...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring activated...
17:21 , Apr 13, 2018 |  BC Week In Review  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed on April 12 to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and ABP-201,...
17:20 , Apr 12, 2018 |  BC Extra  |  Financial News

Abpro planning $69M NASDAQ listing

Antibody company Abpro Corp. (Woburn, Mass.) filed to raise up to $69 million in an IPO on NASDAQ underwritten by UBS, Wells Fargo, Nomura and Oppenheimer. Abpro's two lead programs, ABP-100 and ABP-201, are designed to...
21:49 , Dec 2, 2016 |  BC Week In Review  |  Company News

Abpro, AstraZeneca deal

The MedImmune LLC unit of AstraZeneca and Abpro partnered to develop MedImmune's preclinical bispecific antibody that targets angiopoietin 2 (ANG2; ANGPT2) and VEGF for multiple undisclosed indications. Abpro will use its DiversImmune platform to further...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Abpro, Massachusetts General Hospital deal

Abpro and the hospital partnered to discover and co-develop mAbs in cancer, inflammation and autoimmunity. The partners will use Abpro’s DiversImmune antibody discovery platform. Abpro will have commercialization rights to resulting antibodies. Abpro declined to...
07:00 , May 30, 2016 |  BC Week In Review  |  Company News

Abpro, Brigham and Women’s Hospital deal

Abpro and the hospital partnered to discover and co-develop mAbs for fibrosis. The partners will use Abpro’s DiversImmune antibody discovery platform. Abpro will have commercialization rights to resulting antibodies. Abpro declined to disclose financial terms,...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Company News

Abpro, Essex Bio-Technology Ltd. deal

Abpro partnered with Essex to co-develop and commercialize mAbs in immune-oncology and ophthalmology using Abpro’s DiversImmune discovery platform. Abpro received a $3.5 million equity investment from Essex and an “undisclosed amount from affiliates.” Abpro will...